Tanaka A S, Silva M M, Torquato R J, Noguti M A, Sampaio C A, Fritz H, Auerswald E A
Departamento de Bioquímica, UNIFESP-EPM, São Paulo, Brazil.
FEBS Lett. 1999 Sep 10;458(1):11-6. doi: 10.1016/s0014-5793(99)01106-0.
The recombinant phage antibody system pCANTAB 5E has been used to display functionally active leech-derived tryptase inhibitor (LDTI) on the tip of the filamentous M13 phage. A limited combinatorial library of 5.2 x 10(4) mutants was created with a synthetic LDTI gene, using a degenerated oligonucleotide and the pCANTAB 5E phagemid. The mutations were restricted to the P1-P4' positions of the reactive site. Fusion phages and appropriate host strains containing the phagemids were selected after binding to thrombin and DNA sequencing. The variants LDTI-2T (K8R, I9V, S10, K11W, P12A), LDTI-5T (K8R, I9V, S10, K11S, P12L) and LDTI-10T (K8R, I9L, S10, K11D, P12I) were produced with a Saccharomyces cerevisiae expression system. The new inhibitors, LDTI-2T and -5T, prolong the blood clotting time, inhibit thrombin (Ki 302 nM and 28 nM) and trypsin (Ki 6.4 nM and 2.1 nM) but not factor Xa, plasma kallikrein or neutrophil elastase. The variant LDTI-10T binds to thrombin but does not inhibit it. The relevant reactive site sequences of the thrombin inhibiting variants showed a strong preference for arginine in position P1 (K8R) and for valine in P1' (I9V). The data indicate further that LDTI-5T might be a model candidate for generation of active-site directed thrombin inhibitors and that LDTI in general may be useful to generate specific inhibitors suitable for a better understanding of enzyme-inhibitor interactions.
重组噬菌体抗体系统pCANTAB 5E已被用于在丝状M13噬菌体的尖端展示功能活性的水蛭衍生的胰蛋白酶抑制剂(LDTI)。使用简并寡核苷酸和pCANTAB 5E噬菌粒,用合成的LDTI基因创建了一个5.2×10⁴个突变体的有限组合文库。突变被限制在反应位点的P1 - P4'位置。在与凝血酶结合并进行DNA测序后,选择融合噬菌体和含有噬菌粒的合适宿主菌株。变体LDTI - 2T(K8R、I9V、S10、K11W、P12A)、LDTI - 5T(K8R、I9V、S10、K11S、P12L)和LDTI - 10T(K8R、I9L、S10、K11D、P12I)通过酿酒酵母表达系统产生。新的抑制剂LDTI - 2T和 - 5T延长了血液凝固时间,抑制凝血酶(Ki分别为302 nM和28 nM)和胰蛋白酶(Ki分别为6.4 nM和2.1 nM),但不抑制因子Xa、血浆激肽释放酶或中性粒细胞弹性蛋白酶。变体LDTI - 10T与凝血酶结合但不抑制它。凝血酶抑制变体的相关反应位点序列显示,P1位置强烈偏好精氨酸(K8R),P1'位置强烈偏好缬氨酸(I9V)。数据进一步表明,LDTI - 5T可能是产生活性位点导向的凝血酶抑制剂的模型候选物,并表明一般来说,LDTI可能有助于产生适合更好理解酶 - 抑制剂相互作用的特异性抑制剂。